Investigational new drugs for the treatment of chronic renal failure: an overview of the literature.

Chiara Terzo, Guido Gembillo, Valeria Cernaro, Elisa Longhitano, Vincenzo Calabrese, Chiara Casuscelli, Luigi Peritore, Domenico Santoro

Expert opinion on investigational drugs 2024 Apr

filter terms:

Chronic kidney disease (CKD) is widespread throughout the world, with a high social and health impact. It is considered a 'silent killer' for its sudden onset without symptoms in the early stages of the disease. The main goal of nephrologists is to slow the progression of kidney disease and treat the associated symptoms with a range of new medications. The aim of this systematic review is to analyze the new investigational drugs for the treatment of chronic renal failure. Data were obtained from the available scientific literature and from the ClinicalTrials.gov website. Among the drugs currently being researched, SGLT2 inhibitors appear to be the most promising drugs for the treatment of CKD, has they have slower progression of CKD and protection of cardiorenal function. An important role in the future of CKD treatment is played by autologous cell-therapy, which appears to be a new frontier in the treatment of CKD. Other therapeutic strategies are currently being investigated and have been shown to slow the progression of CKD. However, further studies are needed to determine whether these approaches may offer benefits in slowing the progression of CKD in the near future.

Citation

Chiara Terzo, Guido Gembillo, Valeria Cernaro, Elisa Longhitano, Vincenzo Calabrese, Chiara Casuscelli, Luigi Peritore, Domenico Santoro. Investigational new drugs for the treatment of chronic renal failure: an overview of the literature. Expert opinion on investigational drugs. 2024 Apr;33(4):319-334